drugset / Trial / NCT06848075
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the treatment of moderate or severe migraine.
Timeline
- Start
- 2025-03-05
- Primary completion
- 2025-08-11
- Completion
- 2025-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elismetrep | Small molecule | — | Oral |